Product Description
PG11047 is a novel conformationally restricted analog of the natural polyamine spermine that lowers cellular endogenous polyamine levels and competitively inhibits natural polyamine functions leading to cancer cell growth inhibition. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3115432/)
Mechanisms of Action: PT Analogue
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Progen
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Lymphoma|Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00705653 |
NCT00705653 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2009-08-01 |
2019-03-18 |
Treatments |
|
NCT00293488 |
PROGEN-SL002 | P1 |
Completed |
Lymphoma |
2008-09-01 |
2019-03-21 |
Treatments |